Hospital venture arm backs Bioliberty's €2.95m Series A extension
The Edinburgh and Boston rehabilitation startup has added four institutional investors, including the investment arm of Tampa General Hospital. Its total funding now stands at €12.07 million.
Bioliberty has raised a €2.95 million Series A extension, equivalent to $3.3 million. The round takes the company's total funding to €12.07 million, or $13.5 million.
The company had previously raised €9.12 million ($10.2 million) across pre-Series A and Series A rounds.
Four new institutional backers joined: TGH Ventures, the investment arm of Tampa General Hospital; Ballad Ventures; Belfast-based Whiterock; and 25m Health. Two of those are tied to American hospital systems, which tells you who the company expects to sell to.
Bioliberty was founded in 2020 by Rowan Armstrong, Ross O'Hanlon, Conan Bradley and Shéa Quinn, all from Northern Ireland. Armstrong is chief executive.
The company makes soft-robotic equipment for upper-limb recovery, aimed mainly at stroke patients and others with mobility-limiting neurological conditions.
The product has three parts. Lifehub is a portable control unit that runs therapy sessions, Lifeglov is an air-powered robotic glove that helps patients open and strengthen a hand, and Lifemind is a clinician dashboard that collects therapy data and generates clinical notes using AI.
Lifehub and Lifeglov are FDA-listed in the United States. Bioliberty began selling there commercially in 2025.
The company says the technology was developed alongside inpatient rehabilitation facilities, that sessions can start in under five minutes, and that patients complete more repetitions per session. Those are its own figures.
Ethan Clark, therapy manager at Methodist Rehabilitation Hospital, is quoted by the company saying its therapists have implemented the system and that patients are seeing gains in function.
Bioliberty ran a clinical study with the Mount Sinai health system in 2024. Its US base is in Boston.
The money is earmarked for three things: moving the technology into patients' homes, linking rehabilitation data across care settings, and adding AI features to support clinical decisions.
That is the pitch to a hospital investor. A rehabilitation provider loses sight of a patient the moment they are discharged, and a device that keeps recording repetitions at home closes that gap on the provider's own terms.
For founders selling into healthcare, the structure is the lesson. Bioliberty took an extension rather than a fresh round, and used it to bring in buyers' capital — a hospital system's venture arm is a customer with an incentive to see the product work. The trade is a narrower set of future buyers and a roadmap shaped by what those institutions need next.